More Cost-Effective To Use Cetuximab In Patients With Wild-Type KRAS Gene
Older Women More Likely To Receive Lower Chemotherapy Doses, Study Finds
ASTRO Issues Statement On APBI For Breast Cancer
Denosumab Demonstrates Superiority Over Zometa For Bone Metastases
Lymphedema Education Helps Reduce Symptoms, Study Finds
Exercise May Help Combat Leukemia Patients’ Fatigue
Cranial Radiation Eliminated With Personalized Chemo
Young Early-Stage Patients Can Preserve Fertility
Limb-Sparing Surgery May Not Offer Better Quality of Life
AIDS Patients Face Higher Risk Of HPV-Related Cancers As Immunosuppression Grows
Budesonide Not Beneficial For Diarrhea In Melanoma
NCI Cooperative Group Clinical Trials Approved
Trending Stories
- Vinay Prasad’s CV inaccurately claims past membership on the President’s Cancer Panel
- Breakthrough Therapy designation, ASCO plenary, and NEJM publication notwithstanding, breast cancer drug camizestrant gets a No from ODAC
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - CBER Director Vinay Prasad dared to “say no to drugs”
- J. Craig Venter’s work was foundational to cancer advancement of the past 25 years
- Prasad’s “deceit,” plus, ODAC’s tough decision against biomarker-based progression assessment (for now)
